Zhen Zhang

List of Publications by Year
in descending order

21 papers	4,744 citations	430874 18 h-index	677142 22 g-index
23 all docs	23 docs citations	23 times ranked	5156 citing authors

#	Article	IF	Citations
1	A global registry of fractional flow reserve (FFR)â€“guided management during routine care: Study design, baseline characteristics and outcomes of invasive management. Catheterization and Cardiovascular Interventions, 2020, 96, E423-E431.	1.7	3
2	Three-Year Outcomes With the Absorb Bioresorbable Scaffold. Circulation, 2018, 137, 464-479.	1.6	152
3	The Eastâ€“West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts. American Heart Journal, 2018, 206, 61-71.	2.7	2
4	Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable ScaffoldÂfor Treatment of PatientsÂWithÂDiabetes Mellitus. JACC: Cardiovascular Interventions, 2017, 10, 42-49.	2.9	21
5	3-Year Clinical Outcomes WithÂEverolimus-Eluting BioresorbableÂCoronary Scaffolds. Journal of the American College of Cardiology, 2017, 70, 2852-2862.	2.8	202
6	2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet, The, 2017, 390, 760-772.	13.7	163
7	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet, The, 2016, 387, 1277-1289.	13.7	253
8	Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: Design of and rationale for the ABSORB III randomized trial. American Heart Journal, 2015, 170, 641-651.e3.	2.7	34
9	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. New England Journal of Medicine, 2015, 373, 1905-1915.	27.0	554
10	Functional data analysis for point processes with rare events. Statistica Sinica, 2014, , .	0.3	10
11	Adverse Cardiovascular Events Arising From Atherosclerotic Lesions With and Without Angiographic Disease Progression. JACC: Cardiovascular Imaging, 2012, 5, S95-S105.	5.3	24
12	Characteristics and Clinical Significance of Angiographically Mild Lesions in Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S86-S94.	5.3	23
13	Coronary Plaque Composition, Morphology, and Outcomes in Patients With and Without Chronic Kidney Disease Presenting With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S53-S61.	5.3	93
14	Residual Plaque Burden in Patients With Acute Coronary Syndromes After Successful Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2012, 5, S76-S85.	5.3	40
15	Longitudinal Distribution of Plaque Burden and Necrotic Coreâ€“Rich Plaques in Nonculprit Lesions of Patients Presenting With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S10-S18.	5.3	67
16	Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes. JACC: Cardiovascular Imaging, 2012, 5, S42-S52.	5.3	113
17	The XIENCE nanoâ„¢ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. Catheterization and Cardiovascular Interventions, 2012, 80, 546-553.	1.7	49
18	Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. EuroIntervention, 2012, 8, 929-938.	3.2	78

#	Article	IF	Citations
19	A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine, 2011, 364, 226-235.	27.0	2,721
20	Functional density synchronization. Computational Statistics and Data Analysis, 2011, 55, 2234-2249.	1.2	24
21	Longevityâ€“fertility tradeâ€offs in the tephritid fruit fly, Anastrepha ludens, across dietaryâ€restriction gradients. Aging Cell, 2008, 7, 470-477.	6.7	108